来自肝脏的Neuregulin1α刺激胰腺补偿性β细胞增生,在胰岛素耐药性方面发挥作用
Takatomo Arai1, Eriko Hayashi1, Sumie Maeda1
1Department of Life Science and Medical Bioscience, Graduate School of Advanced Science and Engineering, Waseda University, Tokyo, Japan.
Nature communications
|March 14, 2025
概括
肝脏蛋白Neuregulin1α驱动胰腺β细胞扩张,以满足2型糖尿病患者的胰岛素需求. 这种肝因通过增加功能性β细胞质量来增强葡萄糖控制.
科学领域:
- 内分泌学 在内分泌学.
- 代谢性疾病研究研究
- 分子生物学分子生物学
背景情况:
- 补偿性胰岛岛增生对于管理胰岛素需求增加至关重要,但根本机制尚未完全理解.
- 识别调节β细胞适应的因素对于理解和治疗2型糖尿病至关重要.
- 肝脏分泌的因素在胰腺β细胞功能中的作用需要进一步研究.
研究的目的:
- 在2型糖尿病的背景下,研究肝脏衍生的Neuregulin1α (NRG1α) 在调解补偿性胰腺β细胞增殖中的作用.
- 阐明NRG1α影响β细胞扩张和功能的信号通路.
- 在临床前模型和人类患者中评估血清NRG1α水平与代谢状态之间的相关性.
主要方法:
- 利用一种食诱导肥胖的小鼠模型来研究NRG1α表达及其对葡萄糖平衡的影响.
- 产生了缺乏肝脏NRG1或β细胞ErbB3的转基因小鼠,以评估它们在饮食诱导的代谢变化中的作用.
- 采用了西方抹黑和ERK信号通路分析,以了解NRG1α作用的分子机制.
- 测量了与代谢功能障碍相关的脂肪性肝病 (MASLD) 和不同血糖控制的人类患者的血清NRG1α水平.
主要成果:
- 在肥胖诱导饮食的雄性小鼠中,肝脏NRG1α表达和血清水平升高.
- 缺少肝脏NRG1或β细胞ErbB3的小鼠表现出由于β细胞扩张和胰岛素分泌减少而导致葡萄糖处理受损.
- NRG1α激活了ERBB2/3-ERK信号通路,促进了β细胞的增殖,而不影响葡萄糖刺激的胰岛素分泌.
- 患有MASLD和肥胖的人类患者的血清NRG1α水平增加,而患有MASLD和2型糖尿病的人的血清NRG1α水平显著降低.
结论:
- 神经素1α 作为一种肝激素,促进功能β细胞质量的补偿扩张.
- NRG1α信号传递是适应β细胞功能以增加胰岛素需求的关键机制,特别是在2型糖尿病等疾病中.
- 血清NRG1α水平可以作为一种生物标志物,用于在肝病和肥胖时的代谢状态和β细胞适应.
相关概念视频
Tissue Renewal without Stem Cells
1.7K
After cellular or tissue damage, the resident stem cells present in the human body can locally repair and regenerate the damaged tissue or organ. However, even though some tissues do not have stem cells, they can repair and regenerate with the help of pre-existing cells. For example, beta cells of the pancreas and hepatocytes of the liver can divide to renew and regenerate the tissue. Here, both cell division and cell death are well regulated by homeostasis.
However, failure of such a system...
However, failure of such a system...
1.7K
Insulin Secretory Vesicles
4.8K
Insulin secretory vesicles release insulin to stimulate blood glucose uptake and regulate carbohydrate metabolism. When the blood glucose levels increase, glucose enters the pancreatic β-islet cells through glucose transporters. Once inside, glucose is metabolized through glycolysis, the citric acid cycle, and the electron transport chain, producing ATP. This increase in ATP concentration closes ATP-sensitive potassium channels, leading to depolarization of the membrane and the opening of...
4.8K
Glucose Homeostasis: Pancreatic Islets and Insulin Secretion
1.0K
The pancreatic islets comprising only 1%-2% of the volume are highly vascularized and innervated mini-organs. They contain five endocrine cell types, including β cells that secrete insulin, which is synthesized as a single polypeptide chain, preproinsulin, processed to proinsulin, and finally to insulin and C-peptide. This process is complex and regulated, involving the Golgi complex, the endoplasmic reticulum, and the secretory granules of the β cell.
Insulin and C-peptide are...
Insulin and C-peptide are...
1.0K
Liver Regeneration
3.2K
The liver is an important organ in vertebrates that plays an essential role in metabolism. It is also responsible for storing and redistributing nutrients such as carbohydrates, fats, and vitamins in the body. Additionally, the liver releases bile salts which are critical for digesting food and eliminating toxic metabolites from the body.
Cells of Liver
The liver comprises four major types of cells— hepatocytes, stellate, Kupffer, and sinusoidal endothelial cells. The hepatocytes are...
Cells of Liver
The liver comprises four major types of cells— hepatocytes, stellate, Kupffer, and sinusoidal endothelial cells. The hepatocytes are...
3.2K
Hormones Regulating Blood Glucose
3.0K
Insulin is released by beta cells of the pancreas when blood glucose levels are high. It facilitates glucose absorption and utilization in insulin-dependent cells with insulin receptors on their plasma membranes. Insulin promotes glucose uptake by increasing the number of glucose transport proteins in the cell membrane, allowing glucose to enter the cell. As a result, glucose utilization and ATP production are enhanced.
In addition to accelerating glucose uptake and utilization, insulin has...
In addition to accelerating glucose uptake and utilization, insulin has...
3.0K
Glucagon-like Receptor Agonists
281
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
281


